Friday, September 12, 2025

Mind Medicine To Raise Further $19.5 Million In Bought Deal

Mind Medicine (NEO: MMED) this morning announced that it is conducting yet another round of financing, after having raised $92.1 million just two months ago. The latest round of financing will take the form of a bought deal, lead by Canaccord Genuity, with funds largely said to come from one large institutional investor.

The financing will see Mind Medicine sell a total of 6.0 million units of the company at a price of $3.25 each, for gross proceeds of $19.5 million. Each unit is to contain one subordinate voting share and one half of a subordinate voting share warrant. Each warrant is valid for a period of three years from the date of issuance, and contains an exercise price of $4.40 per share.

Warrants issued under the offering are also subject to an acceleration clause, whereby the company can force the early expiry of the warrants in the event that the firms equity trades above $6.90 for a period of five consecutive trading days on a volume weighted basis.

The offering is currently slated to close March 9, 2021.

Proceeds from the financing will be used for the firms experiential LSD program, its LSD microdosing program, and Project Albert, the firms mental health tech platform, and general working capital purposes.

Mind Medicine last traded at $3.64 on the Neo Exchange.


Information for this briefing was found via Sedar and MindMed. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Avino Q2 Earnings: Steady As She Goes

MEG Energy: Cenovus Comes In With $7.9 BILLION Offer

Orla Mining Q2 Earnings: Musselwhite Changes Everything

Recommended

Northern Superior Expands Philibert With 350 Metre Step Out Testing 1.10 g/t Gold Over 25.5 Metres

Goliath Resources Hits 18.58 g/t Gold Over 5.00 Metres At Surebet

Related News

Mindmed: Canaccord Calls Financing “Puzzling And Unusual”

This past week Mind Medicine Inc. (NEO: MMED) announced that they would be doing a...

Saturday, October 1, 2022, 01:04:00 PM

Mind Medicine Sees CEO Sell $24.7 Million In Company Stock

It appears that uplisting to the Nasdaq is good for business. Or, at least for...

Wednesday, May 26, 2021, 10:14:37 AM

MindMed Presents Positive Data Studying LSD In Treating Anxiety Disorders

Mind Medicine Inc. (NEO: MMED), more commonly known as MindMed, announced today that its top...

Wednesday, May 11, 2022, 10:27:55 AM

MindMed To Begin Trading On The Nasdaq April 27

MindMed (NEO: MMED) is moving up to the big leagues. The psychedelics company this morning...

Friday, April 23, 2021, 09:11:58 AM

Psychedelics & The Need For Digital Therapeutic Solutions In Treating Mental Health

In terms of investment dollar inflows, one of the largest focuses of 2020 has arguably...

Sunday, November 1, 2020, 09:00:00 AM